EP1784212A2 - Polypeptides for inducing a protective immune response against staphylococcus aureus - Google Patents

Polypeptides for inducing a protective immune response against staphylococcus aureus

Info

Publication number
EP1784212A2
EP1784212A2 EP05858353A EP05858353A EP1784212A2 EP 1784212 A2 EP1784212 A2 EP 1784212A2 EP 05858353 A EP05858353 A EP 05858353A EP 05858353 A EP05858353 A EP 05858353A EP 1784212 A2 EP1784212 A2 EP 1784212A2
Authority
EP
European Patent Office
Prior art keywords
polypeptide
seq
aureus
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05858353A
Other languages
German (de)
French (fr)
Other versions
EP1784212A4 (en
Inventor
Donna I Montgomery
Kathrin Ute Jansen
Annaliesa S. Anderson
William I Macclements
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP1784212A2 publication Critical patent/EP1784212A2/en
Publication of EP1784212A4 publication Critical patent/EP1784212A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/085Staphylococcus

Definitions

  • Staphylococcus aureus is a pathogen responsible for a wide range of diseases and conditions.
  • diseases and conditions caused by S. aureus include bacteremia, infective endocarditis, folliculitis, furuncle, carbuncle, impetigo, bullous impetigo, cellulitis, botryomyosis, toxic shock syndrome, scalded skin syndrome, central nervous system infections, infective and inflammatory eye disease, osteomyletitis and other infections of joints and bones, and respiratory tract infections. (The Staphylococci in Human Disease, Crossley and Archer (eds.), Churchill Livingstone Inc. 1997.)
  • Immunological based strategies can be employed to control 5. aureus infections and the spread of S. aureus. Immunological based strategies include passive and active immunization. Passive immunization employs immunoglobulins targeting 5. aureus. Active immunization induces immune responses against 5. aureus.
  • S. aureus vaccines target S. aureus polysaccharides and polypeptides. Targeting can be achieved using suitable 5. aureus polysaccharides or polypeptides as vaccine components. Examples of polysaccharides that may be employed as possible vaccine components include S. aureus type 5 and type 8 capsular polysaccharides. (Shinefield et ah, N. Eng. J. Med. 346:491- 496, 2002.) Examples of polypeptides that may be employed as possible vaccine components include collagen adhesin, fibrinogen binding proteins, and clumping factor. (Mamo et al., FEMS Immunology and Medical Microbiology 70:47-54, 1994, Nilsson et ah, J. Clin.
  • SEQ ID NO: 1 is a truncated derivative of a full-length S. aureus polypeptide.
  • the full-length naturally occurring polypeptide is referred to herein as full-length "ORF2331".
  • a His-tagged derivative of SEQ ID NO: 1 was found to produce a protective immune response against S. aureus.
  • a first aspect of the present invention describes a polypeptide immunogen comprising an amino acid sequence at least 85% identical to SEQ ID NO: 1, wherein the polypeptide does not contain an amino terminus provided by amino acids 1-20 of SEQ ID NO: 3 and the polypeptide provides protective immunity against S. aureus.
  • SEQ ID NO: 3 provides a full length ORF2331 polypeptide, wherein amino acids 1-20 provide the amino terminus domain containing a signal sequence.
  • Reference to comprising an amino acid sequence at least 85% identical to SEQ ID NO: 1 indicates that a SEQ ID NO: 1 related region is present and additional polypeptides regions may be present.
  • Percent identity (also referred to as percent identical) to a reference sequence is determined by aligning the polypeptide sequence with the reference sequence and determining the number of identical amino acids in the corresponding regions.
  • an immunogen comprising an amino acid sequence that provides protective immunity against S. aureus and one or more additional regions or moieties covalently joined to the amino acid sequence at the carboxyl terminus or amino terminus, wherein each region or moiety is independently selected from a region or moiety having at least one of the following properties: enhances the immune response, facilitates purification, or facilitates polypeptide stability.
  • additional region or moiety indicates a region or moiety different from a ORF2331 region. The additional region or moiety can be, for example, an additional polypeptide region or a non-peptide region.
  • compositions able to induce protective immunity against 5. aureus in a patient comprising a pharmaceutically acceptable carrier and an immunologically effective amount of an immunogen that provides protective immunity against S. aureus.
  • An immunologically effective amount is an amount sufficient to provide protective immunity against S. aureus infection.
  • the amount should be sufficient to significantly prevent the likelihood or severity of a 5. aureus infection.
  • a nucleic acid comprising a recombinant gene encoding a polypeptide that provides protective immunity against 5. aureus.
  • a recombinant gene contains recombinant nucleic acid encoding a polypeptide along with regulatory elements for proper transcription and processing (which may include translational and post translational elements).
  • the recombinant gene can exist independent of a host genome or can be part of a host genome.
  • a recombinant nucleic acid is nucleic acid that by virtue of its sequence and/or form does not occur in nature.
  • examples of recombinant nucleic acid include purified nucleic acid, two or more nucleic acid regions combined together that provides a different nucleic acid than found in nature, and the absence of one or more nucleic acid regions (e.g., upstream or downstream regions) that are naturally associated with each other.
  • the cell comprises a recombinant gene encoding a polypeptide that provides protective immunity against 5. aureus.
  • Another aspect of the present invention describes a method of making a polypeptide that provides protective immunity against S. aureus.
  • the method involves growing a recombinant cell containing recombinant nucleic acid encoding the polypeptide and purifying the polypeptide.
  • Another aspect of the present invention describes a polypeptide that provides protective immunity against S. aureus made by a process comprising the steps of growing a recombinant cell containing recombinant nucleic acid encoding the polypeptide in a host and purifying the polypeptide. Different host cells can be employed.
  • Another aspect of the present invention describes a method of inducing a protective immune response in a patient against 5. aureus.
  • the method comprises the step of administering to the patient an immunologically effective amount of an immunogen that provides protective immunity against S. aureus.
  • reference to "or” indicates either or both possibilities. Occasionally phrases such as "and/or” are used to highlight either or both possibilities.
  • Figure 1 illustrates the amino acid sequence of SEQ ID NO: 1.
  • Figure 2 illustrate a sequence comparison between SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5.
  • SEQ ID NO: 2 is a His-tagged construct of SEQ ID NO: 1. The SEQ ID NO: 1 region is shown underlined.
  • SEQ ID NOs: 3, 4 and 5 are different ORF2331 sequences. Some amino acid differences between the sequences are shown in bold.
  • Figure 3 illustrates a nucleic acid sequence SEQ ID NO: 6 encoding SEQ ID NO: 2. The region encoding SEQ ID NO: 1 is shown in bold.
  • Figure 4 illustrate survival data using a SEQ ED NO: 2 polypeptide in aluminum hydroxyphosphate adjuvant (AHP).
  • the polypeptide is referred to as "SEQ 2".
  • SEQ ED NO: 1 is a His-Tag derivative of SEQ ED NO: 1. The His-Tag facilitates polypeptide purification and identification.
  • SEQ ED NO: 1 is a derivative of a full-length 5. aureus polypeptide designated full- length ORF2331 (SEQ ED NO: 3). SEQ ED NO: 1 was obtained from ORF2331 by removing the first 20 amino acids of SEQ ED NO: 3. The first 20 amino acids contain the signal sequence.
  • Polypeptides structurally related to SEQ ED NO: 1 include polypeptides containing corresponding regions present in different 5. aureus strains and derivatives of naturally occurring regions.
  • the amino acid sequence of SEQ ED NO: 1 is illustrated in Figure 1. ORF2331 Sequences
  • ORF2331 related sequences have been given different designations in different references. Examples of different designations are provided in Kuroda et al, Lancet 357: 1225-1240, 2001 (SAV0361 and SA0359); and Baba et al, Lancet 359:1819-1827, 2002 (MW0227).
  • a polypeptide sequence corresponding to an ORF2331 related sequence appears to be provided in different patent publications. (Meinke et al, International Publication Number WO 02/059148, published August 1, 2002, and Masignani et al., International Publication Number WO 02/094868, published November 28, 2002.)
  • ORF2331 sequences can be identified based on the presence of a high degree of sequence similarity or contiguous amino acids compared to a known ORF2331 sequence. Contiguous amino acids provide characteristic tags.
  • a naturally occurring ORF2331 sequence is a sequence found in a Staphylococcus, preferably S. aureus, having at least 20, at least 30, or at least 50 contiguous amino acids as in SEQ ID NO: 1; and/or having at least 85% sequence similarity or identity with SEQ ID NO: 1.
  • Sequence similarity can be determined by different algorithms and techniques well known in the art. Generally, sequence similarity is determined by techniques aligning two sequences to obtain maximum amino acid identity, allowing for gaps, additions and substitutions in one of the sequences.
  • Sequence similarity can be determined, for example, using a local alignment tool utilizing the program lalign (developed by Huang and Miller, Adv. Appl. Math. 72:337-357, 1991, for the «sim» program).
  • the options and environment variables are:-f # Penalty for the first residue a gap (-14 by default); -g # Penalty for each additional residue in a gap (-4 by default)-s str (SMATRIX) the filename of an alternative scoring matrix file.
  • PAM250 is used by default-w # (LINLEN) output line length for sequence alignments (60).
  • SEQ ID NO: 1 related polypeptides contain an amino acid sequence at least 85% identical to SEQ ID NO: 1.
  • Reference to "polypeptide” does not provide a minimum or maximum size limitation.
  • a polypeptide at least 85% identical to SEQ ID NO: 1 contains up to about 25 amino acid alterations from SEQ ID NO: 1.
  • the SEQ ID NO: 1 related polypeptide is at 90%, at least 94%, or at least 99% identical to SEQ ID NO: 1; differs from SEQ ID NO: 1 by 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid alterations; or consists essentially of SEQ ID NO: 1.
  • Each amino acid alteration is independently either a deletion, substitution, or addition.
  • references to "consists essentially" of indicated amino acids indicates that the referred to amino acids are present and additional amino acids may be present.
  • the additional amino acids can be at the carboxyl or amino terminus. In different embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 additional amino acids are present.
  • a preferred additional amino acid is an amino terminus methionine.
  • Alterations can be made to SEQ TD NO: 1 to obtain derivatives that can induce protective immunity against S. aureus. Alterations can be performed, for example, to obtain a derivative retaining the ability to induce protective immunity against 5. aureus or to obtain a derivative that in addition to providing protective immunity also has a region that can achieve a particular purpose.
  • the sequence comparison provided in Figure 2 can be used to guide the design of potential alterations to SEQ ID NO: 1.
  • alterations can be made taking into account other ORF2331 sequences and known properties of amino acids.
  • the replacement amino acid should have one or more similar properties such as approximately the same charge and/or size and/or polarity and/or hydrophobicity.
  • valine for leucine, arginine for lysine, and asparagine for glutamine are good candidates for not causing a change in polypeptide functioning.
  • Alterations to achieve a particular purpose include those designed to facilitate production or efficacy of the polypeptide; or cloning of the encoded nucleic acid.
  • Polypeptide production can be facilitated through the use of an initiation codon (e.g., coding for methionine) suitable for recombinant expression. The methionine may be later removed during cellular processing.
  • Cloning can be facilitated by, for example, the introduction of restriction sites which can be accompanied by amino acid additions or changes.
  • Efficacy of a polypeptide to induce an immune response can be enhanced through epitope enhancement.
  • Epitope enhancement can be performed using different techniques such as those involving alteration of anchor residues to improve peptide affinity for MHC molecules and those increasing affinity of the peptide-MHC complex for a T-cell receptor. (Berzofsky et ah, Nature Review 7:209-219, 2001.)
  • the polypeptide is a purified polypeptide.
  • a "purified polypeptide” is present in an environment lacking one or more other polypeptides with which it is naturally associated and/or is represented by at least about 10% of the total protein present.
  • the purified polypeptide represents at least about 50%, at least about 75%, or at least about 95% of the total protein in a sample or preparation.
  • the polypeptide is "substantially purified.”
  • a substantially purified polypeptide is present in an environment lacking all, or most, other polypeptides with which the polypeptide is naturally associated.
  • aureus polypeptide is present in an environment lacking all, or most, other S. aureus polypeptides.
  • An environment can be, for example, a sample or preparation.
  • purified does not require a polypeptide to undergo any purification and may include, for example, a chemically synthesized polypeptide that has not been purified.
  • Polypeptide stability can be enhanced by modifying the polypeptide carboxyl or amino terminus.
  • modifications include amino terminus protecting groups such as acetyl, propyl, succinyl, benzyl, benzyloxycarbonyl or /-butyloxycarbonyl; and carboxyl terminus protecting groups such as amide, methylamide, and ethylamide.
  • polypeptide immunogen is part of an immunogen containing one or more additional regions or moieties covalently joined to the polypeptide at the carboxyl terminus or amino terminus, where each region or moiety is independently selected from a region or moiety having at least one of the following properties: enhances the immune response, facilitates purification, or facilitates polypeptide stability.
  • Polypeptide stability can be enhanced, for example, using groups such as polyethylene glycol that may be present on the amino or carboxyl terminus.
  • Polypeptide purification can be enhanced by adding a group to the carboxyl or amino terminus to facilitate purification.
  • groups that can be used to facilitate purification include polypeptides providing affinity tags.
  • affinity tags include a six-histidine tag, trpE, glutathione and maltose-binding protein.
  • the ability of a polypeptide to produce an immune response can be enhanced using groups that generally enhance an immune response.
  • groups that can be joined to a polypeptide to enhance an immune response against the polypeptide include cytokines such as IL-2. (Buchan et al., 2000. Molecular Immunology _?7:545-552.)
  • Polypeptides can be produced using standard techniques including those involving chemical synthesis and those involving purification from a cell producing the polypeptide.
  • Techniques for chemical synthesis of polypeptides are well known in the art. (See e.g., Vincent, Peptide and Protein Drug Delivery, New York, N.Y., Decker, 1990.) Techniques for recombinant polypeptide production and purification are also well known in the art. (See for example, Ausubel, Current Protocols in
  • Obtaining polypeptides from a cell is facilitated using recombinant nucleic acid techniques to produce the polypeptide.
  • Recombinant nucleic acid techniques for producing a polypeptide involve introducing, or producing, a recombinant gene encoding the polypeptide in a cell and expressing the polypeptide.
  • a recombinant gene contains nucleic acid encoding a polypeptide along with regulatory elements for polypeptide expression.
  • the recombinant gene can be present in a cellular genome or can be part of an expression vector.
  • the regulatory elements that may be present as part of a recombinant gene include those naturally associated with the polypeptide encoding sequence and exogenous regulatory elements not naturally associated with the polypeptide encoding sequence. Exogenous regulatory elements such as an exogenous promoter can be useful for expressing a recombinant gene in a particular host or increasing the level of expression.
  • the regulatory elements that are present in a recombinant gene include a transcriptional promoter, a ribosome binding site, a terminator, and an optionally present operator.
  • a preferred element for processing in eukaryotic cells is a polyadenylation signal.
  • an expression vector in addition to a recombinant gene also contains an origin of replication for autonomous replication in a host cell, a selectable marker, a limited number of useful restriction enzyme sites, and a potential for high copy number.
  • expression vectors are cloning vectors, modified cloning vectors, specifically designed plasmids and viruses.
  • nucleic acid sequences Due to the degeneracy of the genetic code, a large number of different encoding nucleic acid sequences can be used to code for a particular polypeptide.
  • the degeneracy of the genetic code arises because almost all amino acids are encoded by different combinations of nucleotide triplets or "codons". Amino acids are encoded by codons as follows:
  • Suitable cells for recombinant nucleic acid expression of SEQ K) NO: 1 related polypeptides are prokaryotes and eukaryotes.
  • prokaryotic cells include E. col ⁇ , members of the Staphylococcus genus, such as 5. aureus; members of the Lactobacillus genus, such as L. plantarum; members of the Lactococcus genus, such as L. lactis; and members of the Bacillus genus, such as B. subtilis.
  • eukaryotic cells include mammalian cells; insect cells; yeast cells such as members of the Saccharomyces genus ⁇ e.g., S.
  • members of the Pichia genus e.g., P. pastoris
  • members of the Hansenula genus e.g., H. polymorpha
  • members of the Kluyveromyces genus e.g., K. lactis or K. fragilis
  • members of the Schizosaccharomyces genus e.g., S. pombe.
  • Codon optimization includes use of more preferred codons. Techniques for codon optimization in different hosts are well known in the art.
  • SEQ ID NO: 1 related polypeptides may contain post translational modifications, for example, N-linked glycosylation, O-linked glycosylation, or acetylation.
  • Reference to "polypeptide” or an "amino acid" sequence of a polypeptide includes polypeptides containing one or more amino acids having a structure of a post-translational modification from a host cell, such as a yeast host.
  • Post translational modifications can be produced chemically or by making use of suitable hosts. For example, in S. cerevisiae the nature of the penultimate amino acid appears to determine whether the N-terminal methionine is removed.
  • the nature of the penultimate amino acid also determines whether the N-terminal amino acid is N ⁇ -acetylated (Huang et al., Biochemistry 26: 8242-8246, 1987).
  • Another example includes a polypeptide targeted for secretion due to the presence of a secretory leader (e.g., signal peptide), where the protein is modified by N-linked or O-linked glycosylation. (Kukuruzinska et al., Ann. Rev. Biochem. 56:915-944, 1987.)
  • Adjuvants are substances that can assist an immunogen in producing an immune response. Adjuvants can function by different mechanisms such as one or more of the following: increasing the antigen biologic or immunologic half-life; improving antigen delivery to antigen- presenting cells; improving antigen processing and presentation by antigen-presenting cells; and inducing production of immunomodulatory cytokines. (Vogel, Clinical Infectious Diseases 30(suppl. 3):S266-270, 2000.)
  • adjuvants can be employed to assist in the production of an immune response.
  • adjuvants include aluminum hydroxide, aluminum phosphate, or other salts of aluminum, calcium phosphate, DNA CpG motifs, monophosphoryl lipid A, cholera toxin, E.
  • a "patient” refers to a mammal capable of being infected with S. aureus.
  • a patient can be treated prophylactically or therapeutically.
  • Prophylactic treatment provides sufficient protective immunity to reduce the likelihood, or severity, of a 5. aureus infection.
  • Therapeutic treatment can be performed to reduce the severity of a 5. aureus infection.
  • Prophylactic treatment can be performed using a vaccine containing an immunogen described herein. Such treatment is preferably performed on a human.
  • Vaccines can be administered to the general population or to those persons at an increased risk of S. aureus infection.
  • aureus infection include health care workers; hospital patients; patients with a weakened immune system; patients undergoing surgery; patients receiving foreign body implants, such a catheter or a vascular device; patients facing therapy leading to a weakened immunity; and persons in professions having an increased risk of burn or wound injury.
  • Non-human patients that can be infected with 5. aureus include cows, pigs, sheep, goats, rabbits, horses, dogs, cats and mice. Treatment of non-human patients is useful in protecting pets and livestock, and in evaluating the efficacy of a particular treatment.
  • Combination Vaccines include cows, pigs, sheep, goats, rabbits, horses, dogs, cats and mice. Treatment of non-human patients is useful in protecting pets and livestock, and in evaluating the efficacy of a particular treatment.
  • SEQ ID NO: 1 related polypeptides can be used alone, or in combination with other immunogens, to induce an immune response.
  • Additional immunogens that may be present include: one or more additional S. aureus immunogens, such as those referenced in the Background of the Invention supra; one or more immunogens targeting one or more other Staphylococcus organisms such as 5. epidermidis, S. haemolyticus, S. warneri, or S.lugunensis; and one or more immunogens targeting other infections organisms.
  • the animal model system was used to evaluate the efficacy of an immunogen to produce a protective immune response against 5. aureus.
  • the animal model was a slow kinetics lethality model involving S. aureus prepared from cells in stationary phase, appropriately titrated, and intravenously administered. This slow kinetics of death provides sufficient time for the specific immune defense to fight off the bacterial infection (e.g., 10 days rather 24 hours).
  • S. aureus cells in stationary phase can be obtained from cells grown on solid medium.
  • aureus can be grown from about 18 to about 24 hours under conditions where the doubling time is about 20-30 minutes.
  • S. aureus can be isolated from solid or liquid medium using standard techniques to maintain S. aureus potency. Isolated 5. aureus can be stored, for example, at -7O 0 C as a washed high density suspension (> 10 9 colony forming units (CFU)/mL) in phosphate buffered saline containing glycerol.
  • the S. aureus challenge should have a potency providing about 80 to 90% death in an animal model over a period of about 7 to 10 days starting on the first or second day.
  • Titration experiments can be performed using animal models to monitor the potency of the stored Staphylococcus inoculum. The titration experiments can be performed about one to two weeks prior to an inoculation experiment.
  • Immunogens can be formulated and administered to a patient using the guidance provided herein along with techniques well known in the art. Guidelines for pharmaceutical administration in general are provided in, for example, Vaccines Eds. Plotkin and Orenstein, W.B.
  • Pharmaceutically acceptable carriers facilitate storage and administration of an immunogen to a patient.
  • Pharmaceutically acceptable carriers may contain different components such as a buffer, sterile water for injection, normal saline or phosphate buffered saline, sucrose, histidine, salts and polysorbate.
  • Immunogens can be administered by different routes such as subcutaneous, intramuscular, or mucosal.
  • Subcutaneous and intramuscular administration can be performed using, for example, needles or jet-injectors.
  • Suitable dosing regimens are preferably determined taking into account factors well known in the art including age, weight, sex and medical condition of the patient; the route of administration; the desired effect; and the particular compound employed.
  • the immunogen can be used in multi-dose vaccine formats. It is expected that a dose would consist of the range of 1.0 ⁇ g to 1.0 mg total polypeptide. In different embodiments of the present invention the range is 0.01 mg to 1.0 mg and
  • booster doses may subsequently be administered to maintain or boost antibody titers.
  • An example of a dosing regime would be day 1, 1 month, a third dose at either 4, 6 or 12 months, and additional booster doses at distant times as needed.
  • a SEQ ID NO: 1 related polypeptide can be used to generate antibodies and antibody fragments that bind to the polypeptide or to 5. aureus.
  • Such antibodies and antibody fragments have different uses including use in polypeptide purification, S. aureus identification, or in therapeutic or prophylactic treatment against 5. aureus infection.
  • Antibodies can be polyclonal or monoclonal. Techniques for producing and using antibodies are well known in the art. Examples of such techniques are described in Ausubel, Current Protocols in Molecular Biology, John Wiley, 1987-2002, Harlow et al., Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory, 1988, and Kohler et al, Nature 256:495-497, 1975. EXAMPLES
  • SEQ ID NO: 1 a His-tagged derivative of SEQ ID NO: 1, was used to provide protective immunity.
  • the protein was designed to be expressed from the pET16 vector with the His-Tag residues encoded by the vector.
  • the vector provides the initiating Met codon followed by a GIy codon, the 10 His-Tag, and an additional 12 codons for Ser Ser GIy His He GIu GIy Arg His Met Leu GIu. (Amino acids 1-24 of SEQ ID NO: 2.)
  • the designed DNA sequence encodes a 194 amino acid altered form of mature ORF2331.
  • the ORF2331 DNA sequence was translated using Vector NTI software and the resulting amino acid sequence (SEQ ID NO: 1) was analyzed.
  • PCR primers were designed to amplify the gene starting at the 21 st residue (Asn) to remove a signal sequence and membrane binding site and ending prior to the stop codon at the terminal His residue.
  • the forward PCR primers contained an Xhol restriction site to facilitate cloning into the expression vector.
  • the reverse PCR primer included a BIpI restriction site to facilitate cloning into the expression vector and a stop codon.
  • PCR amplified sequences were digested with Xhol and BIpI then ligated into the pET16b vector (Novagen) digested with Xhol and BIpI.
  • the ligation reaction was transformed into E. coli strain NovaBlue and colonies selected by growth in LB with 100 ⁇ g/mL ampicillin. DNA minipreps were made (Qiagen), and insert integrity determined by restriction digestion and sequence confirmation. A clone was selected containing no DNA changes from the desired sequence.
  • E. coli BLR(DE3) cells (Novagen) were transformed and grown on LB plates containing ampicillin (100 ug/ml). Liquid LB (amplicillin) cultures were set up by inoculating with single colonies from the LB (ampicillin) plates and incubated at 37 0 C, 250 rpm overnight. The overnight culture was diluted back into fresh LB (ampicillin), grown until the A 60O was between 0.6 and 1.0, an un-induced cell pellet harvested and the rest of the culture induced by the addition of IPTG to final concentrations of 1 mM and allowed to express for three hours. Cell pellets were harvested from 1 ml culture by centrifugation at 5000 x g for 3 minutes at room temperature.
  • E. coli cell paste Frozen recombinant E. coli cell paste (48 grams) was thawed and resuspended in four volumes of Lysis Buffer (50 mM sodium phosphate, pH 8.0, 0.15 M NaCl, 2 mM magnesium chloride, 10 mM imidazole, 0.1% Tween-80, and 0.02% sodium azide.
  • Lysis Buffer 50 mM sodium phosphate, pH 8.0, 0.15 M NaCl, 2 mM magnesium chloride, 10 mM imidazole, 0.1% Tween-80, and 0.02% sodium azide.
  • Benzonase EM #1.01697.0002
  • protease inhibitor cocktail was added to the cell suspension at one tablet per 15 ml (CompleteTM, EDTA-Free, Roche # 1873580).
  • a lysate was prepared with a microfluidizer.
  • the Lysate was stirred overnight at 4°C, and was clarified by centrifugation at 10,800 x g for 30 minutes at 4°C.
  • the supernatant was filtered through a glass-fiber pre-filter (Millipore) and NaCl was added to a final concentration of 0.5 M from a 5 M stock solution.
  • the Filtered Supernatant was added to Ni-NTA agarose chromatography resin (Qiagen #30250) and the slurry was mixed overnight at 4°C.
  • the slurry of chromatography resin was poured into a chromatography column and the non-bound fraction was collected by gravity from the column outlet.
  • the column was washed with five column volumes of Wash Buffer (50 mM sodium phosphate, pH 8.0, 0.3 M NaCl, 0.1% Tween-80, and 20 mM imidazole).
  • the column was eluted with Elution Buffer (50 mM sodium phosphate, pH 8.0, 0.3 M NaCl, 0.1% Tween-80, and 0.3 M imidazole).
  • Ni-MAC Product Fractions containing protein were identified by dot blot on nitrocellulose membrane with Ponceau-S staining, and fractions containing the highest protein concentrations were pooled to make the Ni-MAC Product.
  • the Ni-EVlAC Product was fractionated by SEC.
  • SEC fractions containing the product protein were identified by SDS/PAGE with Coomassie staining.
  • Product-containing SEC fractions were pooled to make the SEC Product.
  • the SEC Product was filtered with a CUNO Zeta-Plus BioCap filter to remove endotoxin. The Filtrate was sterile-filtered and adsorbed on aluminum hydroxyphosphate adjuvant at a final concentration of 0.2 mg/ml.
  • mice Twenty BALB/c mice were immunized with three doses of a SEQ ID NO: 2 polypeptide
  • Aluminum hydroxyphosphate adjuvant (AHP) is described by Klein et ah, Journal of Pharmaceutical Sciences 89,
  • mice 311-321, 2000. 30 mice were vaccinated with three doses of AHP alone as an adjuvant control group.
  • the doses were administered as two 50 ⁇ l intramuscular injections on days 0, 7 and 21.
  • the mice were bled on day 28, and their sera were screened by ELSIA for reactivity to immunogen ORF2331.
  • mice were challenged with S. aureus (7 X 10 8 CFU/ml) and evaluated against the control set of 30 mice that had just been immunized with AHP. The mice were monitored over an 11 day period for survival. At the end of the experiment 8 of 20 (40%) mice survived the SEQ ID NO: 2 immunized group compared to 6 of 30 (20%) surviving in the AHP control group.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention features polypeptides comprising an amino acid sequence structurally related to SEQ ID NO: 1 and uses of such polypeptides. SEQ ID NO: 1 is a truncated derivative of a full-length S. aureus polypeptide. The full-length naturally occurring polypeptide is referred to herein as full-length “ORF2331”. A His-tagged derivative of SEQ ID NO: 1 was found to produce a protective immune response against S. aureus.

Description

TITLE OF THE INVENTION
POLYPEPTIDES FOR INDUCING A PROTECTIVE IMMUNE RESPONSE AGAINST
STAPHYLOCOCCUS A UREUS
CROSS-REFERENCE TO RELATED APPLICATIONS
The present application claims the benefit of U.S. Provisional Application No. 60/585,698, filed July 6, 2004 hereby incorporated by reference herein.
BACKGROUND OF THE INVENTION The references cited throughout the present application are not admitted to be prior art to the claimed invention.
Staphylococcus aureus is a pathogen responsible for a wide range of diseases and conditions. Examples of diseases and conditions caused by S. aureus include bacteremia, infective endocarditis, folliculitis, furuncle, carbuncle, impetigo, bullous impetigo, cellulitis, botryomyosis, toxic shock syndrome, scalded skin syndrome, central nervous system infections, infective and inflammatory eye disease, osteomyletitis and other infections of joints and bones, and respiratory tract infections. (The Staphylococci in Human Disease, Crossley and Archer (eds.), Churchill Livingstone Inc. 1997.)
Immunological based strategies can be employed to control 5. aureus infections and the spread of S. aureus. Immunological based strategies include passive and active immunization. Passive immunization employs immunoglobulins targeting 5. aureus. Active immunization induces immune responses against 5. aureus.
Potential S. aureus vaccines target S. aureus polysaccharides and polypeptides. Targeting can be achieved using suitable 5. aureus polysaccharides or polypeptides as vaccine components. Examples of polysaccharides that may be employed as possible vaccine components include S. aureus type 5 and type 8 capsular polysaccharides. (Shinefield et ah, N. Eng. J. Med. 346:491- 496, 2002.) Examples of polypeptides that may be employed as possible vaccine components include collagen adhesin, fibrinogen binding proteins, and clumping factor. (Mamo et al., FEMS Immunology and Medical Microbiology 70:47-54, 1994, Nilsson et ah, J. Clin. Invest. 101:2640-2649, 1998, Josefsson et ah, The Journal of Infectious Diseases 754:1572-1580, 2001.) Information concerning S. aureus polypeptide sequences has been obtained from sequencing the 5. aureus genome. (Kuroda et ah, Lancet 357:1225-1240, 2001, Baba et ah, Lancet 359: 1819-1827, 2000, Kunsch et ah, European Patent Publication EP 0 786 519, published July 30, 1997.) To some extent bioinformatics has been employed in efforts to characterize polypeptide sequences obtained from genome sequencing. (Kunsch et ah, European Patent Publication EP 0 786 519, published July 30, 1997.) Techniques such as those involving display technology and sera from infected patients can be used in an effort to identify genes coding for potential antigens. (Foster et al, International Publication Number WO 01/98499, published December 27, 2001, Meinke et al, International Publication Number WO 02/059148, published August 1, 2002, Etz et al, PNAS 99:6573-6578, 2002.)
SUMMARY OF THE INVENTION
The present invention features polypeptides comprising an amino acid sequence structurally related to SEQ ID NO: 1 and uses of such polypeptides. SEQ ID NO: 1 is a truncated derivative of a full-length S. aureus polypeptide. The full-length naturally occurring polypeptide is referred to herein as full-length "ORF2331". A His-tagged derivative of SEQ ID NO: 1 was found to produce a protective immune response against S. aureus.
Reference to "protective" immunity or immune response indicates a detectable level of protection against S. aureus infection. The level of protection can be assessed using animal models such as those described herein. Thus, a first aspect of the present invention describes a polypeptide immunogen comprising an amino acid sequence at least 85% identical to SEQ ID NO: 1, wherein the polypeptide does not contain an amino terminus provided by amino acids 1-20 of SEQ ID NO: 3 and the polypeptide provides protective immunity against S. aureus. SEQ ID NO: 3 provides a full length ORF2331 polypeptide, wherein amino acids 1-20 provide the amino terminus domain containing a signal sequence. Reference to comprising an amino acid sequence at least 85% identical to SEQ ID NO: 1 indicates that a SEQ ID NO: 1 related region is present and additional polypeptides regions may be present. Reference to the polypeptide not containing an amino terminus provided by amino acids 1-20 of SEQ ID NO: 3, indicates that if additional polypeptide regions are present the polypeptide does not have an amino terminus provided by amino acids 1-20 of SEQ ID NO: 3. Percent identity (also referred to as percent identical) to a reference sequence is determined by aligning the polypeptide sequence with the reference sequence and determining the number of identical amino acids in the corresponding regions. This number is divided by the total number of amino acids in the reference sequence (e.g., SEQ ID NO: 1) and then multiplied by 100 and rounded to the nearest whole number. Another aspect of the present invention describes an immunogen comprising an amino acid sequence that provides protective immunity against S. aureus and one or more additional regions or moieties covalently joined to the amino acid sequence at the carboxyl terminus or amino terminus, wherein each region or moiety is independently selected from a region or moiety having at least one of the following properties: enhances the immune response, facilitates purification, or facilitates polypeptide stability. Reference to "additional region or moiety" indicates a region or moiety different from a ORF2331 region. The additional region or moiety can be, for example, an additional polypeptide region or a non-peptide region.
Another aspect of the present invention describes a composition able to induce protective immunity against 5. aureus in a patient. The composition comprises a pharmaceutically acceptable carrier and an immunologically effective amount of an immunogen that provides protective immunity against S. aureus.
An immunologically effective amount is an amount sufficient to provide protective immunity against S. aureus infection. The amount should be sufficient to significantly prevent the likelihood or severity of a 5. aureus infection.
Another aspect of the present invention describes a nucleic acid comprising a recombinant gene encoding a polypeptide that provides protective immunity against 5. aureus. A recombinant gene contains recombinant nucleic acid encoding a polypeptide along with regulatory elements for proper transcription and processing (which may include translational and post translational elements). The recombinant gene can exist independent of a host genome or can be part of a host genome.
A recombinant nucleic acid is nucleic acid that by virtue of its sequence and/or form does not occur in nature. Examples of recombinant nucleic acid include purified nucleic acid, two or more nucleic acid regions combined together that provides a different nucleic acid than found in nature, and the absence of one or more nucleic acid regions (e.g., upstream or downstream regions) that are naturally associated with each other.
Another aspect of the present invention describes a recombinant cell. The cell comprises a recombinant gene encoding a polypeptide that provides protective immunity against 5. aureus.
Another aspect of the present invention describes a method of making a polypeptide that provides protective immunity against S. aureus. The method involves growing a recombinant cell containing recombinant nucleic acid encoding the polypeptide and purifying the polypeptide.
Another aspect of the present invention describes a polypeptide that provides protective immunity against S. aureus made by a process comprising the steps of growing a recombinant cell containing recombinant nucleic acid encoding the polypeptide in a host and purifying the polypeptide. Different host cells can be employed.
Another aspect of the present invention describes a method of inducing a protective immune response in a patient against 5. aureus. The method comprises the step of administering to the patient an immunologically effective amount of an immunogen that provides protective immunity against S. aureus. Unless particular terms are mutually exclusive, reference to "or" indicates either or both possibilities. Occasionally phrases such as "and/or" are used to highlight either or both possibilities.
Reference to open-ended terms such as "comprises" allows for additional elements or steps. Occasionally phrases such as "one or more" are used with or without open-ended terms to highlight the possibility of additional elements or steps.
Unless explicitly stated reference to terms such as "a" or "an" is not limited to one. For example, "a cell" does not exclude "cells". Occasionally phrases such as one or more are used to highlight the presence of a plurality.
Other features and advantages of the present invention are apparent from the additional descriptions provided herein including the different examples. The provided examples illustrate different components and methodology useful in practicing the present invention. The examples do not limit the claimed invention. Based on the present disclosure the skilled artisan can identify and employ other components and methodology useful for practicing the present invention.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 illustrates the amino acid sequence of SEQ ID NO: 1.
Figure 2 illustrate a sequence comparison between SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5. SEQ ID NO: 2 is a His-tagged construct of SEQ ID NO: 1. The SEQ ID NO: 1 region is shown underlined. SEQ ID NOs: 3, 4 and 5 are different ORF2331 sequences. Some amino acid differences between the sequences are shown in bold.
Figure 3 illustrates a nucleic acid sequence SEQ ID NO: 6 encoding SEQ ID NO: 2. The region encoding SEQ ID NO: 1 is shown in bold.
Figure 4 illustrate survival data using a SEQ ED NO: 2 polypeptide in aluminum hydroxyphosphate adjuvant (AHP). The polypeptide is referred to as "SEQ 2".
DETAILED DESCRIPTION OF THE INVENTION
The ability of SEQ ED NO: 1 related polypeptides to provide protective immunity is illustrated in the Examples provided below using SEQ ED NO: 2. SEQ ED NO: 2 is a His-Tag derivative of SEQ ED NO: 1. The His-Tag facilitates polypeptide purification and identification. SEQ ED NO: 1 is a derivative of a full-length 5. aureus polypeptide designated full- length ORF2331 (SEQ ED NO: 3). SEQ ED NO: 1 was obtained from ORF2331 by removing the first 20 amino acids of SEQ ED NO: 3. The first 20 amino acids contain the signal sequence.
Polypeptides structurally related to SEQ ED NO: 1 include polypeptides containing corresponding regions present in different 5. aureus strains and derivatives of naturally occurring regions. The amino acid sequence of SEQ ED NO: 1 is illustrated in Figure 1. ORF2331 Sequences
ORF2331 related sequences have been given different designations in different references. Examples of different designations are provided in Kuroda et al, Lancet 357: 1225-1240, 2001 (SAV0361 and SA0359); and Baba et al, Lancet 359:1819-1827, 2002 (MW0227). A polypeptide sequence corresponding to an ORF2331 related sequence appears to be provided in different patent publications. (Meinke et al, International Publication Number WO 02/059148, published August 1, 2002, and Masignani et al., International Publication Number WO 02/094868, published November 28, 2002.)
Other naturally occurring ORF2331 sequences can be identified based on the presence of a high degree of sequence similarity or contiguous amino acids compared to a known ORF2331 sequence. Contiguous amino acids provide characteristic tags. In different embodiments, a naturally occurring ORF2331 sequence is a sequence found in a Staphylococcus, preferably S. aureus, having at least 20, at least 30, or at least 50 contiguous amino acids as in SEQ ID NO: 1; and/or having at least 85% sequence similarity or identity with SEQ ID NO: 1. Sequence similarity can be determined by different algorithms and techniques well known in the art. Generally, sequence similarity is determined by techniques aligning two sequences to obtain maximum amino acid identity, allowing for gaps, additions and substitutions in one of the sequences.
Sequence similarity can be determined, for example, using a local alignment tool utilizing the program lalign (developed by Huang and Miller, Adv. Appl. Math. 72:337-357, 1991, for the «sim» program). The options and environment variables are:-f # Penalty for the first residue a gap (-14 by default); -g # Penalty for each additional residue in a gap (-4 by default)-s str (SMATRIX) the filename of an alternative scoring matrix file. For protein sequences, PAM250 is used by default-w # (LINLEN) output line length for sequence alignments (60).
SEO ID NO: 1 Related Polypeptides
SEQ ID NO: 1 related polypeptides contain an amino acid sequence at least 85% identical to SEQ ID NO: 1. Reference to "polypeptide" does not provide a minimum or maximum size limitation. A polypeptide at least 85% identical to SEQ ID NO: 1 contains up to about 25 amino acid alterations from SEQ ID NO: 1. In different embodiments, the SEQ ID NO: 1 related polypeptide is at 90%, at least 94%, or at least 99% identical to SEQ ID NO: 1; differs from SEQ ID NO: 1 by 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid alterations; or consists essentially of SEQ ID NO: 1. Each amino acid alteration is independently either a deletion, substitution, or addition. Reference to "consists essentially" of indicated amino acids indicates that the referred to amino acids are present and additional amino acids may be present. The additional amino acids can be at the carboxyl or amino terminus. In different embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 additional amino acids are present. A preferred additional amino acid is an amino terminus methionine.
Alterations can be made to SEQ TD NO: 1 to obtain derivatives that can induce protective immunity against S. aureus. Alterations can be performed, for example, to obtain a derivative retaining the ability to induce protective immunity against 5. aureus or to obtain a derivative that in addition to providing protective immunity also has a region that can achieve a particular purpose. The sequence comparison provided in Figure 2 can be used to guide the design of potential alterations to SEQ ID NO: 1. In addition, alterations can be made taking into account other ORF2331 sequences and known properties of amino acids.
Generally, in substituting different amino acids to retain activity it is preferable to exchange amino acids having similar properties. Factors that can be taken into account for an amino acid substitution include amino acid size, charge, polarity, and hydrophobicity. The effect of different amino acid R-groups on amino acid properties are well known in the art. (See, for example, Ausubel, Current Protocols in Molecular Biology, John Wiley, 1987-2002, Appendix 1C.)
In exchanging amino acids to maintain activity, the replacement amino acid should have one or more similar properties such as approximately the same charge and/or size and/or polarity and/or hydrophobicity. For example, substituting valine for leucine, arginine for lysine, and asparagine for glutamine are good candidates for not causing a change in polypeptide functioning.
Alterations to achieve a particular purpose include those designed to facilitate production or efficacy of the polypeptide; or cloning of the encoded nucleic acid. Polypeptide production can be facilitated through the use of an initiation codon (e.g., coding for methionine) suitable for recombinant expression. The methionine may be later removed during cellular processing. Cloning can be facilitated by, for example, the introduction of restriction sites which can be accompanied by amino acid additions or changes.
Efficacy of a polypeptide to induce an immune response can be enhanced through epitope enhancement. Epitope enhancement can be performed using different techniques such as those involving alteration of anchor residues to improve peptide affinity for MHC molecules and those increasing affinity of the peptide-MHC complex for a T-cell receptor. (Berzofsky et ah, Nature Review 7:209-219, 2001.)
Preferably, the polypeptide is a purified polypeptide. A "purified polypeptide" is present in an environment lacking one or more other polypeptides with which it is naturally associated and/or is represented by at least about 10% of the total protein present. In different embodiments, the purified polypeptide represents at least about 50%, at least about 75%, or at least about 95% of the total protein in a sample or preparation.
In an embodiment, the polypeptide is "substantially purified." A substantially purified polypeptide is present in an environment lacking all, or most, other polypeptides with which the polypeptide is naturally associated. For example, a substantially purified 5. aureus polypeptide is present in an environment lacking all, or most, other S. aureus polypeptides. An environment can be, for example, a sample or preparation.
Reference to "purified" or "substantially purified" does not require a polypeptide to undergo any purification and may include, for example, a chemically synthesized polypeptide that has not been purified.
Polypeptide stability can be enhanced by modifying the polypeptide carboxyl or amino terminus. Examples of possible modifications include amino terminus protecting groups such as acetyl, propyl, succinyl, benzyl, benzyloxycarbonyl or /-butyloxycarbonyl; and carboxyl terminus protecting groups such as amide, methylamide, and ethylamide. In an embodiment of the present invention the polypeptide immunogen is part of an immunogen containing one or more additional regions or moieties covalently joined to the polypeptide at the carboxyl terminus or amino terminus, where each region or moiety is independently selected from a region or moiety having at least one of the following properties: enhances the immune response, facilitates purification, or facilitates polypeptide stability. Polypeptide stability can be enhanced, for example, using groups such as polyethylene glycol that may be present on the amino or carboxyl terminus.
Polypeptide purification can be enhanced by adding a group to the carboxyl or amino terminus to facilitate purification. Examples of groups that can be used to facilitate purification include polypeptides providing affinity tags. Examples of affinity tags include a six-histidine tag, trpE, glutathione and maltose-binding protein.
The ability of a polypeptide to produce an immune response can be enhanced using groups that generally enhance an immune response. Examples of groups that can be joined to a polypeptide to enhance an immune response against the polypeptide include cytokines such as IL-2. (Buchan et al., 2000. Molecular Immunology _?7:545-552.)
Polypeptide Production
Polypeptides can be produced using standard techniques including those involving chemical synthesis and those involving purification from a cell producing the polypeptide. Techniques for chemical synthesis of polypeptides are well known in the art. (See e.g., Vincent, Peptide and Protein Drug Delivery, New York, N.Y., Decker, 1990.) Techniques for recombinant polypeptide production and purification are also well known in the art. (See for example, Ausubel, Current Protocols in
Molecular Biology, John Wiley, 1987-2002.)
Obtaining polypeptides from a cell is facilitated using recombinant nucleic acid techniques to produce the polypeptide. Recombinant nucleic acid techniques for producing a polypeptide involve introducing, or producing, a recombinant gene encoding the polypeptide in a cell and expressing the polypeptide.
A recombinant gene contains nucleic acid encoding a polypeptide along with regulatory elements for polypeptide expression. The recombinant gene can be present in a cellular genome or can be part of an expression vector. The regulatory elements that may be present as part of a recombinant gene include those naturally associated with the polypeptide encoding sequence and exogenous regulatory elements not naturally associated with the polypeptide encoding sequence. Exogenous regulatory elements such as an exogenous promoter can be useful for expressing a recombinant gene in a particular host or increasing the level of expression. Generally, the regulatory elements that are present in a recombinant gene include a transcriptional promoter, a ribosome binding site, a terminator, and an optionally present operator. A preferred element for processing in eukaryotic cells is a polyadenylation signal.
Expression of a recombinant gene in a cell is facilitated through the use of an expression vector. Preferably, an expression vector in addition to a recombinant gene also contains an origin of replication for autonomous replication in a host cell, a selectable marker, a limited number of useful restriction enzyme sites, and a potential for high copy number. Examples of expression vectors are cloning vectors, modified cloning vectors, specifically designed plasmids and viruses.
Due to the degeneracy of the genetic code, a large number of different encoding nucleic acid sequences can be used to code for a particular polypeptide. The degeneracy of the genetic code arises because almost all amino acids are encoded by different combinations of nucleotide triplets or "codons". Amino acids are encoded by codons as follows:
A=Ala=Alanine: codons GCA, GCC, GCG, GCU
C=Cys=Cysteine: codons UGC, UGU
D=Asp=Aspartic acid: codons GAC, GAU
E=Glu=Glutamic acid: codons GAA, GAG F=Phe=Phenylalanine: codons UUC, UUU
G=Gly=Glycine: codons GGA, GGC, GGG, GGU
H=His=Histidine: codons CAC, CAU
I=Ile=Isoleucine: codons AUA, AUC, AUU
K=Lys=Lysine: codons AAA, AAG L=Leu=Leucine: codons UUA, UUG, CUA, CUC, CUG, CUU M=Met=Methionine: codon AUG N=Asn=Asparagine: codons AAC, AAU p=Pro=Proline: codons CCA, CCC, CCG, CCU Q=Gln=Glutamine: codons CAA, CAG R=Arg=Arginine: codons AGA, AGG, CGA, CGC, CGG, CGU S=Ser=Serine: codons AGC, AGU, UCA, UCC, UCG, UCU T=Thr=Threonine: codons ACA, ACC, ACG, ACU V=Val=Valine: codons GUA, GUC, GUG, GUU W=Trp=Tryptophan: codon UGG Y=Tyr=Tyrosine: codons UAC, UAU
Suitable cells for recombinant nucleic acid expression of SEQ K) NO: 1 related polypeptides are prokaryotes and eukaryotes. Examples of prokaryotic cells include E. colϊ, members of the Staphylococcus genus, such as 5. aureus; members of the Lactobacillus genus, such as L. plantarum; members of the Lactococcus genus, such as L. lactis; and members of the Bacillus genus, such as B. subtilis. Examples of eukaryotic cells include mammalian cells; insect cells; yeast cells such as members of the Saccharomyces genus {e.g., S. cerevisiae), members of the Pichia genus (e.g., P. pastoris), members of the Hansenula genus (e.g., H. polymorpha), members of the Kluyveromyces genus (e.g., K. lactis or K. fragilis) and members of the Schizosaccharomyces genus (e.g., S. pombe).
Techniques for recombinant gene production, introduction into a cell, and recombinant gene expression are well known in the art. Examples of such techniques are provided in references such as Ausubel, Current Protocols in Molecular Biology, John Wiley, 1987-2002, and Sambrook et al, Molecular Cloning, A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory Press, 1989.
If desired, expression in a particular host can be enhanced through codon optimization. Codon optimization includes use of more preferred codons. Techniques for codon optimization in different hosts are well known in the art.
SEQ ID NO: 1 related polypeptides may contain post translational modifications, for example, N-linked glycosylation, O-linked glycosylation, or acetylation. Reference to "polypeptide" or an "amino acid" sequence of a polypeptide includes polypeptides containing one or more amino acids having a structure of a post-translational modification from a host cell, such as a yeast host. Post translational modifications can be produced chemically or by making use of suitable hosts. For example, in S. cerevisiae the nature of the penultimate amino acid appears to determine whether the N-terminal methionine is removed. Furthermore, the nature of the penultimate amino acid also determines whether the N-terminal amino acid is Nα-acetylated (Huang et al., Biochemistry 26: 8242-8246, 1987). Another example includes a polypeptide targeted for secretion due to the presence of a secretory leader (e.g., signal peptide), where the protein is modified by N-linked or O-linked glycosylation. (Kukuruzinska et al., Ann. Rev. Biochem. 56:915-944, 1987.)
Adjuvants Adjuvants are substances that can assist an immunogen in producing an immune response. Adjuvants can function by different mechanisms such as one or more of the following: increasing the antigen biologic or immunologic half-life; improving antigen delivery to antigen- presenting cells; improving antigen processing and presentation by antigen-presenting cells; and inducing production of immunomodulatory cytokines. (Vogel, Clinical Infectious Diseases 30(suppl. 3):S266-270, 2000.)
A variety of different types of adjuvants can be employed to assist in the production of an immune response. Examples of particular adjuvants include aluminum hydroxide, aluminum phosphate, or other salts of aluminum, calcium phosphate, DNA CpG motifs, monophosphoryl lipid A, cholera toxin, E. coli heat-labile toxin, pertussis toxin, muramyl dipeptide, Freund's incomplete adjuvant, MF59, SAF, immunostimulatory complexes, liposomes, biodegradable microspheres, saponins, nonionic block copolymers, muramyl peptide analogues, polyphosphazene, synthetic polynucleotides, IFN-γ, IL-2 and DL-12. (Vogel Clinical Infectious Diseases 30(suppl 3):S266-270, 2000, Klein et al, Journal of Pharmaceutical Sciences 89:311-321, 2000.)
Patients For Inducing Protective Immunity
A "patient" refers to a mammal capable of being infected with S. aureus. A patient can be treated prophylactically or therapeutically. Prophylactic treatment provides sufficient protective immunity to reduce the likelihood, or severity, of a 5. aureus infection. Therapeutic treatment can be performed to reduce the severity of a 5. aureus infection. Prophylactic treatment can be performed using a vaccine containing an immunogen described herein. Such treatment is preferably performed on a human. Vaccines can be administered to the general population or to those persons at an increased risk of S. aureus infection.
Persons with an increased risk of 5. aureus infection include health care workers; hospital patients; patients with a weakened immune system; patients undergoing surgery; patients receiving foreign body implants, such a catheter or a vascular device; patients facing therapy leading to a weakened immunity; and persons in professions having an increased risk of burn or wound injury. (The Staphylococci in Human Disease, Crossley and Archer (ed.), Churchill Livingstone Inc. 1997.)
Non-human patients that can be infected with 5. aureus include cows, pigs, sheep, goats, rabbits, horses, dogs, cats and mice. Treatment of non-human patients is useful in protecting pets and livestock, and in evaluating the efficacy of a particular treatment. Combination Vaccines
SEQ ID NO: 1 related polypeptides can be used alone, or in combination with other immunogens, to induce an immune response. Additional immunogens that may be present include: one or more additional S. aureus immunogens, such as those referenced in the Background of the Invention supra; one or more immunogens targeting one or more other Staphylococcus organisms such as 5. epidermidis, S. haemolyticus, S. warneri, or S.lugunensis; and one or more immunogens targeting other infections organisms.
Animal Model System An animal model system was used to evaluate the efficacy of an immunogen to produce a protective immune response against 5. aureus. The animal model was a slow kinetics lethality model involving S. aureus prepared from cells in stationary phase, appropriately titrated, and intravenously administered. This slow kinetics of death provides sufficient time for the specific immune defense to fight off the bacterial infection (e.g., 10 days rather 24 hours). S. aureus cells in stationary phase can be obtained from cells grown on solid medium.
They can also be obtained from liquid, however the results with cells grown on solid media were more reproducible. Cells can conveniently be grown overnight on solid medium. For example, 5. aureus can be grown from about 18 to about 24 hours under conditions where the doubling time is about 20-30 minutes. S. aureus can be isolated from solid or liquid medium using standard techniques to maintain S. aureus potency. Isolated 5. aureus can be stored, for example, at -7O0C as a washed high density suspension (> 109 colony forming units (CFU)/mL) in phosphate buffered saline containing glycerol.
The S. aureus challenge should have a potency providing about 80 to 90% death in an animal model over a period of about 7 to 10 days starting on the first or second day. Titration experiments can be performed using animal models to monitor the potency of the stored Staphylococcus inoculum. The titration experiments can be performed about one to two weeks prior to an inoculation experiment.
Initial potency for titration experiments can be based on previous experiments. For S. aureus and the animal model strain Becker a suitable potency was generally found in the range of 5 x 108 to 8 x 108 CFU/ml.
Administration
Immunogens can be formulated and administered to a patient using the guidance provided herein along with techniques well known in the art. Guidelines for pharmaceutical administration in general are provided in, for example, Vaccines Eds. Plotkin and Orenstein, W.B.
Sanders Company, 1999; Remington's Pharmaceutical Sciences 2Uh Edition, Ed. Gennaro, Mack
Publishing, 2000; and Modern Pharmaceutics 2nd Edition, Eds. Banker and Rhodes, Marcel Dekker, Inc.,
1990, each of which are hereby incorporated by reference herein. Pharmaceutically acceptable carriers facilitate storage and administration of an immunogen to a patient. Pharmaceutically acceptable carriers may contain different components such as a buffer, sterile water for injection, normal saline or phosphate buffered saline, sucrose, histidine, salts and polysorbate.
Immunogens can be administered by different routes such as subcutaneous, intramuscular, or mucosal. Subcutaneous and intramuscular administration can be performed using, for example, needles or jet-injectors.
Suitable dosing regimens are preferably determined taking into account factors well known in the art including age, weight, sex and medical condition of the patient; the route of administration; the desired effect; and the particular compound employed. The immunogen can be used in multi-dose vaccine formats. It is expected that a dose would consist of the range of 1.0 μg to 1.0 mg total polypeptide. In different embodiments of the present invention the range is 0.01 mg to 1.0 mg and
0.1 mg to 1.0 mg.
The timing of doses depends upon factors well known in the art. After the initial administration one or more booster doses may subsequently be administered to maintain or boost antibody titers. An example of a dosing regime would be day 1, 1 month, a third dose at either 4, 6 or 12 months, and additional booster doses at distant times as needed.
Generation of Antibodies
A SEQ ID NO: 1 related polypeptide can be used to generate antibodies and antibody fragments that bind to the polypeptide or to 5. aureus. Such antibodies and antibody fragments have different uses including use in polypeptide purification, S. aureus identification, or in therapeutic or prophylactic treatment against 5. aureus infection.
Antibodies can be polyclonal or monoclonal. Techniques for producing and using antibodies are well known in the art. Examples of such techniques are described in Ausubel, Current Protocols in Molecular Biology, John Wiley, 1987-2002, Harlow et al., Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory, 1988, and Kohler et al, Nature 256:495-497, 1975. EXAMPLES
Examples are provided below further illustrating different features of the present invention. The examples also illustrate useful methodology for practicing the invention. These examples do not limit the claimed invention.
Example 1 : Protective Immunity
This example illustrates the ability of SEQ ID NO: 1 related polypeptides to provide protective immunity in an animal model. SEQ ID NO: 2, a His-tagged derivative of SEQ ID NO: 1, was used to provide protective immunity.
SEQ ID NO: 2 Cloning and Expression
The protein was designed to be expressed from the pET16 vector with the His-Tag residues encoded by the vector. The vector provides the initiating Met codon followed by a GIy codon, the 10 His-Tag, and an additional 12 codons for Ser Ser GIy His He GIu GIy Arg His Met Leu GIu. (Amino acids 1-24 of SEQ ID NO: 2.) The designed DNA sequence encodes a 194 amino acid altered form of mature ORF2331.
The ORF2331 DNA sequence was translated using Vector NTI software and the resulting amino acid sequence (SEQ ID NO: 1) was analyzed. PCR primers were designed to amplify the gene starting at the 21st residue (Asn) to remove a signal sequence and membrane binding site and ending prior to the stop codon at the terminal His residue. The forward PCR primers contained an Xhol restriction site to facilitate cloning into the expression vector. The reverse PCR primer included a BIpI restriction site to facilitate cloning into the expression vector and a stop codon.
PCR amplified sequences were digested with Xhol and BIpI then ligated into the pET16b vector (Novagen) digested with Xhol and BIpI. The ligation reaction was transformed into E. coli strain NovaBlue and colonies selected by growth in LB with 100 μg/mL ampicillin. DNA minipreps were made (Qiagen), and insert integrity determined by restriction digestion and sequence confirmation. A clone was selected containing no DNA changes from the desired sequence.
E. coli BLR(DE3) cells (Novagen) were transformed and grown on LB plates containing ampicillin (100 ug/ml). Liquid LB (amplicillin) cultures were set up by inoculating with single colonies from the LB (ampicillin) plates and incubated at 370C, 250 rpm overnight. The overnight culture was diluted back into fresh LB (ampicillin), grown until the A60O was between 0.6 and 1.0, an un-induced cell pellet harvested and the rest of the culture induced by the addition of IPTG to final concentrations of 1 mM and allowed to express for three hours. Cell pellets were harvested from 1 ml culture by centrifugation at 5000 x g for 3 minutes at room temperature. Cell pellets were resuspended in 200 μl lysis buffer (Bugbuster, with protease inhibitors, Novagen), then soluble and insoluble fractions of the induced samples were obtained. An equal volume of loading buffer (supplemented with β-mecapto ethanol to 5% final volume) was added prior to heating the samples at 900C for 3 minutes. Extracts were run on Novex 4-20% Tris-Glycine gels and assayed for protein (Coomassie Blue stained) and blotted onto nitrocellulose and probed with anti-HIS6 antibodies (Zymed).
SEQ ID NO: 2 Purification
Frozen recombinant E. coli cell paste (48 grams) was thawed and resuspended in four volumes of Lysis Buffer (50 mM sodium phosphate, pH 8.0, 0.15 M NaCl, 2 mM magnesium chloride, 10 mM imidazole, 0.1% Tween-80, and 0.02% sodium azide. Benzonase (EM #1.01697.0002) was added to the cell suspension at 250 Units/mL), and protease inhibitor cocktail was added to the cell suspension at one tablet per 15 ml (Complete™, EDTA-Free, Roche # 1873580).
A lysate was prepared with a microfluidizer. The Lysate was stirred overnight at 4°C, and was clarified by centrifugation at 10,800 x g for 30 minutes at 4°C. The supernatant was filtered through a glass-fiber pre-filter (Millipore) and NaCl was added to a final concentration of 0.5 M from a 5 M stock solution. The Filtered Supernatant was added to Ni-NTA agarose chromatography resin (Qiagen #30250) and the slurry was mixed overnight at 4°C.
The slurry of chromatography resin was poured into a chromatography column and the non-bound fraction was collected by gravity from the column outlet. The column was washed with five column volumes of Wash Buffer (50 mM sodium phosphate, pH 8.0, 0.3 M NaCl, 0.1% Tween-80, and 20 mM imidazole). The column was eluted with Elution Buffer (50 mM sodium phosphate, pH 8.0, 0.3 M NaCl, 0.1% Tween-80, and 0.3 M imidazole).
Fractions containing protein were identified by dot blot on nitrocellulose membrane with Ponceau-S staining, and fractions containing the highest protein concentrations were pooled to make the Ni-MAC Product. The Ni-EVlAC Product was fractionated by SEC. SEC fractions containing the product protein were identified by SDS/PAGE with Coomassie staining. Product-containing SEC fractions were pooled to make the SEC Product. The SEC Product was filtered with a CUNO Zeta-Plus BioCap filter to remove endotoxin. The Filtrate was sterile-filtered and adsorbed on aluminum hydroxyphosphate adjuvant at a final concentration of 0.2 mg/ml.
Preparation of S. aureus Challenge
S. aureus was grown on TSA plates at 370C overnight. The bacteria were washed from the TSA plates by adding 5 ml of PBS onto a plate and gently resuspending the bacteria with a sterile spreader. The bacterial suspension was spun at 6000 rpm for 20 minutes using a Sorvall RC-5B centrifuge (DuPont Instruments). The pellet was resuspended in 16% glycerol and aliquots were stored frozen at -7O0C. Prior to use, inocula were thawed, appropriately diluted and used for infection. Each stock was titrated at least 3 times to determine the appropriate dose inducing slow kinetics of death in naive mice. The potency of the bacterial inoculum (80 to 90% lethality) was constantly monitored to assure reproducibility of the model. Ten days before each challenge experiment, a group of 10 control animals (immunized with adjuvant alone) were challenged and monitored.
Protection Studies for a SEQ ID NO: 2 Polypeptide
Twenty BALB/c mice were immunized with three doses of a SEQ ID NO: 2 polypeptide
(20 μg per dose) on aluminum hydroxyphosphate adjuvant (450 μg per dose). Aluminum hydroxyphosphate adjuvant (AHP) is described by Klein et ah, Journal of Pharmaceutical Sciences 89,
311-321, 2000. 30 mice were vaccinated with three doses of AHP alone as an adjuvant control group.
The doses were administered as two 50 μl intramuscular injections on days 0, 7 and 21. The mice were bled on day 28, and their sera were screened by ELSIA for reactivity to immunogen ORF2331.
On day 35 of the experiment the mice were challenged with S. aureus (7 X 108 CFU/ml) and evaluated against the control set of 30 mice that had just been immunized with AHP. The mice were monitored over an 11 day period for survival. At the end of the experiment 8 of 20 (40%) mice survived the SEQ ID NO: 2 immunized group compared to 6 of 30 (20%) surviving in the AHP control group.
The results are illustrated in Figure 4.
Other embodiments are within the following claims. While several embodiments have been shown and described, various modifications may be made without departing from the spirit and scope of the present invention.

Claims

WHAT IS CLAIMED IS:
1. A polypeptide immunogen comprising an amino acid sequence at least 85% identical to SEQ ID NO: 1, wherein said polypeptide provides protective immunity against S. aureus, provided that if one or more additional polypeptide regions are present said additional regions do not provide an amino terminus containing amino acids 1-20 of SEQ ID NO: 3.
2. The polypeptide of claim 1, wherein said amino acid sequence is at least 95% identical to SEQ ID NO: 1.
3. The polypeptide of claim 2, wherein said amino acid sequence consists essentially of SEQ ID NO: 1.
4. The polypeptide of claim 3, wherein said polypeptide consists of the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 1 modified with an amino terminus methionine addition, or
SEQ ID NO: 1 modified with an amino terminus methionine-glutamic acid addition.
5. An immunogen comprising an amino acid sequence at least 85% identical to SEQ ID NO: 1, and one or more additional regions or moieties covalently joined to said amino acid sequence at the carboxyl terminus or amino terminus, wherein each region or moiety is independently selected from a region or moiety having at least one of the following properties: enhances the immune response, facilitates purification, or facilitates polypeptide stability.
6. A composition able to induce a protective immune response in a patient comprising an immunologically effective amount of an immunogen comprising an amino acid sequence at least 85% identical to SEQ ID NO: 1 and a pharmaceutically acceptable carrier.
7. The composition of claim 6, wherein said composition further comprises an adjuvant.
8. A nucleic acid comprising a recombinant gene comprising a nucleotide sequence encoding the polypeptide of any one of claims 1-4.
9. The nucleic acid of claim 8, wherein said nucleic acid is an expression vector.
10. A recombinant cell comprising a recombinant gene comprising a nucleotide sequence encoding the polypeptide of any one of claims 1-4.
11. A method of making a 5. aureus polypeptide that provides protective immunity comprising the steps of:
(a) growing the recombinant cell of claim 10 under conditions wherein said polypeptide is expressed; and
(b) purifying said polypeptide.
12. A method of inducing a protective immune response in a patient comprising the step of administering to said patient an immunologically effective amount of an immunogen comprising an amino acid sequence at least 85% identical to SEQ ID NO: 1.
13. The method of claim 12, wherein said immunogen is the immunogen of any one of claims 1-5.
14. The method of claim 12, wherein said patient is a human.
15. The method of claim 14, wherein said patient is treated prophylactically against 5. aureus infection.
16. A method of inducing a protective immune response in a patient comprising the step of administering to said patient an immunologically effective amount of a polypeptide made by the method of claim 11.
EP05858353A 2004-07-06 2005-07-01 Polypeptides for inducing a protective immune response against staphylococcus aureus Withdrawn EP1784212A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58569804P 2004-07-06 2004-07-06
PCT/US2005/023511 WO2007018482A2 (en) 2004-07-06 2005-07-01 Polypeptides for inducing a protective immune response against staphylococcus aureus

Publications (2)

Publication Number Publication Date
EP1784212A2 true EP1784212A2 (en) 2007-05-16
EP1784212A4 EP1784212A4 (en) 2008-09-17

Family

ID=37727742

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05858353A Withdrawn EP1784212A4 (en) 2004-07-06 2005-07-01 Polypeptides for inducing a protective immune response against staphylococcus aureus

Country Status (2)

Country Link
EP (1) EP1784212A4 (en)
WO (1) WO2007018482A2 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT410798B (en) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh METHOD FOR IDENTIFYING, ISOLATING AND PRODUCING ANTIGENS AGAINST A SPECIFIC PATHOGEN
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BABA TADASHI ET AL: "Genome and virulence determinants of high virulence community-acquired MRSA" LANCET (NORTH AMERICAN EDITION), vol. 359, no. 9320, 25 May 2002 (2002-05-25), pages 1819-1827, XP002487239 ISSN: 0099-5355 *
See also references of WO2007018482A2 *

Also Published As

Publication number Publication date
WO2007018482A3 (en) 2007-10-25
EP1784212A4 (en) 2008-09-17
WO2007018482A2 (en) 2007-02-15

Similar Documents

Publication Publication Date Title
AU2005214061B2 (en) Polypeptides for inducing a protective immune response against Staphylococcus aureus
US20070243205A1 (en) Polypeptides for Inducing a Protective Immune Response Against Staphylococcus Aureus
US20070264278A1 (en) Polypeptides for Inducing a Protective Immune Response Against Staphylococcus Aureus
US20080095792A1 (en) Polypeptides For Inducing A Protective Immune Response Against Staphylococcus Aureus
AU2006206577B2 (en) Polypeptides for inducing a protective immune response against Staphylococcus aureus
US20060188515A1 (en) Polypeptides for inducing a protective immune response against staphylococcus aureus
EP1725255A2 (en) Polypeptides for inducing a protective immune response against staphlococcus aureus
EP2376111A1 (en) Polypeptides for inducing a protective immune response against staphylococcus aureus
US8124108B2 (en) Polypeptides for inducing a protective immune response against Staphylococcus epidermidis
US20100104591A1 (en) Polypeptides for inducing a protective immune response against staphylococcus epidermidis
WO2006121664A2 (en) Polypeptides for inducing a protective immune response against staphylococcus aureus
WO2007018482A2 (en) Polypeptides for inducing a protective immune response against staphylococcus aureus

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

DAX Request for extension of the european patent (deleted)
R17D Deferred search report published (corrected)

Effective date: 20071025

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/31 20060101ALI20071231BHEP

Ipc: C12N 1/21 20060101ALI20071231BHEP

Ipc: C12N 15/74 20060101ALI20071231BHEP

Ipc: C12P 21/06 20060101ALI20071231BHEP

Ipc: C07H 21/04 20060101ALI20071231BHEP

Ipc: A61K 39/085 20060101ALI20071231BHEP

Ipc: A61K 39/02 20060101AFI20071231BHEP

17P Request for examination filed

Effective date: 20080425

RBV Designated contracting states (corrected)

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

A4 Supplementary search report drawn up and despatched

Effective date: 20080814

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20081027